BenevolentAI agrees partnership with medical research charity LifeArc
BenevolentAI, announced that it has partnered with LifeArc (formerly MRC Technology), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.
The two-year agreement sees BenevolentAI combine the power of its unique technology in the application of AI for drug discovery with LifeArc’s expertise in translating novel exciting biology into lead stage therapeutic assets.
Both organisations will respectively share confidential molecular disease targets and collaborate to develop them into potential new drugs. This will be done in one of two ways:
BenevolentAI will share disease targets produced by its technology with LifeArc who will then undertake the complex chemistry to create a lead compound. BenevolentAI will then undertake further preclinical and clinical development of the compound.
LifeArc will run molecules or antibodies that it believes may hit a target through BenevolentAI’s technology platform to validate. If validation is confirmed, LifeArc will either continue to partner with BenevolentAI or work with another partner to develop the target further.
Jackie Hunter, Head of Clinical Development at BenevolentAI,commented:
“The combination of our technology and R&D experience, together with LifeArc’s screening and hit to lead capabilities, is powerful. It’s a novel model and I believe that our two organisations’ complementary skills and capabilities will enable the search for, and development of, new medicines to proceed much more quickly.”
Dr Justin Bryans, Director, Drug Discovery, LifeArc commented:
“As a charity we are always eager to pursue opportunities that can lead to new treatments for patients. Exploring promising targets via BenevolentAI’s data mining and insight is an exciting new area for us and we hope to really advance medical science through our collaboration.”